Top videos
Source ABC7, 24 November 2009 An initial single-arm Phase II trial (ACT II) has reported promising preliminary data in 23 patients who received CDX-110 vaccine. Median time to disease progression was 16.6 months and estimated median overall survival was 33.1 months. This compared favorably with data for a historical control group in which median time to progression was 6.4 months and median overall survival was 15.2 months. The study was sponsored by Celldex Therapeutics Inc. of Phillipsburg, NJ
Learn about electromagnetic navigation diagnostic bronchoscopy, a new technology used to diagnose small lung cancer tumors as small as a pencil eraser before they have the chance to spread. Cleveland Clinic physician Dr. Thomas Gildea demonstrates how this endobronchial ultrasound procedure, which involves using a small camera probe inserted thru the nose into the lungs, allows doctors to reach possible cancer in the lungs that they could never reliably get to before
Recurrent varicose veins are a common problem. The patient in this video was operated for great saphenous vein insufficiency and a “neocrosse” occurred after few years. Surgical exploration revealed a “cavernoma” just over the nodes of the crural area, feeding varicose veins of thigh and leg.
The 3rd Annual W. B. Ingalls Memorial
Prostate Health and Cancer Seminar features nationally renowned physicians and scientists presenting the most current study and practices for the diagnosis and treatment of prostate cancer. This day-long program offers in-depth exploration of prostate issues that range from monitoring PSA counts to cutting-edge research to current treatment trends.